retatrutide trial update october 2025 This is exciting. 👀 The TRIUMPH-4 results for Lilly's investigational medication were released, showing weight loss of up to 71 lbs (~28%) over 68 weeks in the highest-dose group—far beyond Retatrutide Commercial Availability Timeline: Key

Pricing in the research market may actually decrease initially as the compound becomes more widely manufactured, but could also become more restricted as regulatory attention increases

Retatrutide, designated LY3437943, is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously

Proper injection technique and consistent timing also matterinjecting at the same time each week (for weekly formulations) helps maintain stable drug levels

Sustained elevation above the normal range carries theoretical concerns regarding cell proliferation, and tesamorelin is contraindicated in individuals with active malignancy

The modest heart rate increase of 5-10 beats per minute appears tolerable in most patients